Today: 18 January 2026
Subscribe
Browse Category

Healthcare News News 9 August 2025 - 29 November 2025

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis Year…
29 November 2025
····
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now. 1. Medicare’s New Drug Prices Hit GSK’s Trelegy and Breo Ellipta The…
26 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and telehealth partners. The changes come just days after the Trump administration struck landmark pricing agreements with Novo Nordisk and Eli…
17 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States. GlobeNewswire TONMYA Officially Launches in the U.S. Tonix announced at 7:00 a.m. EST that TONMYA is available for pharmacy ordering nationwide and can now be…
17 November 2025
·
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire JAZZ…
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal adenocarcinoma, a group that includes cancers of the stomach, gastroesophageal junction, and esophagus. GlobeNewswire The trial compared three regimens: According…
17 November 2025
····
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

What happened today Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) announced that it has successfully achieved target loading concentrations for two topical rapamycin delivery technologies—4% in its lotion and 5% in a dermal patch. The company said it will start manufacturing clinical and stability batches this quarter and is planning clinical testing in the first half of 2026. Initial targets include MLM…
11 November 2025
···
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings Inc. (NASDAQ: ENGN) reported fresh preliminary data this morning from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid (formerly EG‑70) in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS. The readout shows a 62% complete response (CR) at 6 months (n=37), 56% at 3 months (n=62) and 63% CR at any time (n=62)…
11 November 2025
····
Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Company Overview – Innovating in Women’s Health Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick (a female inventor-entrepreneur), Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologies Femasys Gurufocus. The company’s mission is to provide women with minimally invasive, office-based…
3 November 2025
·
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings Stocktitan. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis Stocktitan. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result”…
9 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day Investing. The rally continued on Oct. 1, with PFE closing at $27.21 (another +6.8%) Investing. In total, Pfizer…
2 October 2025
····
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Drug Approvals & Regulatory Developments (In Europe, regulators also made news: the EMA’s committee recommended approving darolutamide (Bayer’s Nubeqa) with hormone therapy for metastatic prostate cancer based on positive Phase 3 data Onclive.) Clinical Trials & Research Breakthroughs Public Health & Policy Industry & Business Updates Sources: Key information and quotes in this report were drawn from Reuters news wires…
9 August 2025
··
1 2

Stock Market Today

  • Nvidia stock muted after China blocks H200 shipments; traders eye earnings and AI-chip roadmap
    January 18, 2026, 1:53 PM EST. NVIDIA shares closed down 0.41% to $186.23 on Friday after a Financial Times report that Chinese customs blocked shipments of the H200 AI processor. Suppliers paused output as the halt looms over Nvidia's supply chain. With markets closed for MLK Day, focus shifts to Tuesday's session and Nvidia's Feb. 25 results. Analysts at Wolfe Research keep Nvidia on the Alpha List, citing a ramp for Blackwell and Rubin chips; they see upside to 2026 revenue if the trend holds. Options activity could amplify moves ahead of expiration. A pause that drags into a formal ban would delay shipments; a temporary pause could ease near-term pressure. The broader semis index rose, but the China hinge remains.
Go toTop